<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="8f1b071b-c7cb-4d07-98d4-fecf70ce8167"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use REZUROCK safely and effectively. See full prescribing information for REZUROCK.<br/>
      <br/>
      <br/>
      <br/>REZUROCK<sup>®</sup> (belumosudil) tablets, for oral use<br/>
      <br/>Initial U.S. Approval: 2021</title>
   <effectiveTime value="20250429"/>
   <setId root="102e4ef4-7f84-4e34-8df1-479c24d1575d"/>
   <versionNumber value="9"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="117510981"/>
            <name>Kadmon Pharmaceuticals, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="650443430"/>
                        <name>Dr. Reddy's Laboratories Limited, CTO Unit-V1</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="79802-200" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="79802-200" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="79802-200" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="015966157"/>
                        <name>Catalent Micron</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="79802-200" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="081301372"/>
                        <name>Gregory Pharmaceutical Holdings, Inc., dba UPM Pharmaceuticals</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="79802-200" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="79802-200" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="79802-200" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="79802-200" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="650645067"/>
                        <name>Daicel Chiral Technologies (I) Pvt. Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="79802-200" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="928861723"/>
                        <name>Carton Service Inc. (dba Pharma Packaging Solutions)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="79802-200" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="79802-200" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="1d9c37b5-387e-4200-ac74-2d0334ef627a"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250429"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="79802-200" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Rezurock</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>belumosudil</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="200"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="834YJF89WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BELUMOSUDIL</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="834YJF89WO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BELUMOSUDIL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="79802-200-30" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20210716"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA214783" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210716"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="yellow" xsi:type="CE">
                              <originalText>Pale Yellow to Yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="14" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">KDM;200</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="5403e444-6c80-4ca6-98ff-6864d0184f91"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.</paragraph>
               </text>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>REZUROCK is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="eb7a91ef-cce2-40a6-b652-a4082b75464e"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Recommended Dosage</content>: 200 mg taken orally once daily with food. (<linkHtml href="#S2.1">2.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="a12cd4fe-4e05-40cf-8879-5dbec282a223"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Recommended Dosage</title>
                     <text>
                        <paragraph>The recommended dose of REZUROCK is 200 mg given orally once daily until progression of chronic GVHD that requires new systemic therapy.</paragraph>
                        <paragraph>Instruct the patient on the following:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Swallow REZUROCK tablets whole. Do not cut, crush, or chew tablets.</item>
                           <item>Take REZUROCK with a meal at approximately the same time each day <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</item>
                           <item>If a dose of REZUROCK is missed, instruct the patient to not take extra doses to make up the missed dose.</item>
                        </list>
                        <paragraph>Treatment with REZUROCK has not been studied in patients with pre-existing severe renal impairment. For patients with pre-existing severe renal impairment, consider the risks and potential benefits before initiating treatment with REZUROCK <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="0d445656-7f2e-40a9-8ef3-1778cfcd0398"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Dosage Modifications for Adverse Reactions</title>
                     <text>
                        <paragraph>Monitor total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) at least monthly.</paragraph>
                        <paragraph>Modify the REZUROCK dosage for adverse reactions as per Table 1.</paragraph>
                        <table width="80%" ID="TABLE1">
                           <caption>Table 1: Recommended Dosage Modifications for REZUROCK for Adverse Reactions</caption>
                           <col width="25%" align="left" valign="top"/>
                           <col width="35%" align="left" valign="top"/>
                           <col width="40%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Adverse Reaction</th>
                                 <th styleCode="Rrule">Severity<footnote ID="K619">Based on CTCAE v 4.03</footnote>
                                 </th>
                                 <th styleCode="Rrule">REZUROCK Dosage Modifications</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule">Hepatotoxicity <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Rrule">Grade 3 AST or ALT (5× to 20× ULN) or Grade 2 bilirubin (1.5× to 3× ULN)</td>
                                 <td styleCode="Rrule">Hold REZUROCK until recovery of bilirubin, AST and ALT to Grade 0–1, then resume REZUROCK at the recommended dose.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule">Grade 4 AST or ALT (more than 20× ULN) or Grade ≥3 bilirubin (more than 3× ULN)</td>
                                 <td styleCode="Rrule">Discontinue REZUROCK permanently.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule">Other adverse reactions <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Rrule">Grade 3</td>
                                 <td styleCode="Rrule">Hold REZUROCK until recovery to  Grade 0–1, then resume REZUROCK at the recommended dose level.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule">Grade 4</td>
                                 <td styleCode="Rrule">Discontinue REZUROCK permanently.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="69b772db-3391-40c1-9559-dee4184fd4b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Dosage Modification Due to Drug Interactions</title>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section>
                           <id root="0bde29ff-82a8-47c6-bafe-9effa78cbd3e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Strong CYP3A Inducers</content>
                              </paragraph>
                              <paragraph>Increase the dosage of REZUROCK to 200 mg twice daily when coadministered with strong CYP3A inducers <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="50fab16d-ed8f-4ca0-8f7d-2d657f8ed17d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Proton Pump Inhibitors</content>
                              </paragraph>
                              <paragraph>Increase the dosage of REZUROCK to 200 mg twice daily when coadministered with proton pump inhibitors <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="c1053c95-eb6e-4427-b4c5-4cae3b974bdd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4	Recommended Dosage in Patients with Hepatic Impairment </title>
                     <text>
                        <paragraph>Avoid use in patients with moderate hepatic impairment (Child-Pugh B) or severe hepatic impairment (Child-Pugh C) without liver GVHD <content styleCode="italics">[see <linkHtml href="#S8.7">Use in Specific Populations (8.7)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>No dosage adjustment is recommended when administering REZUROCK to patients with mild hepatic impairment <content styleCode="italics">[see <linkHtml href="#S8.7">Use in Specific Populations (8.7)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="6cde6853-efcd-40cb-aafa-dc125cc09652"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Each 200 mg belumosudil tablet is a pale yellow film-coated oblong tablet debossed with "KDM" on one side and "200" on the other side.</paragraph>
               </text>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablet: 200 mg. (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="b7f051d2-cb6a-44fb-bc81-4a5ff4207e1c"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="e69570b6-df31-4fb2-b9f7-0a78c16cbaaa"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5	 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Embryo-Fetal Toxicity</content>: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (<linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>, <linkHtml href="#S8.3a">8.3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="efd285dd-0eb5-4e15-8313-7ba5f8e0a753"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 	Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on findings in animals and its mechanism of action, REZUROCK can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of belumosudil to pregnant rats and rabbits during the period of organogenesis caused adverse developmental outcomes including embryo-fetal mortality and malformations at maternal exposures (AUC) less than those in patients at the recommended dose. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with REZUROCK and for one week after the last dose <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3a">8.3)</linkHtml>, <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="797ed561-9846-49ca-b8af-57bc3f41d16b"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common (≥20%) adverse reactions, including laboratory abnormalities, are infections, asthenia, nausea, diarrhea, dyspnea, cough, edema, hemorrhage, abdominal pain, musculoskeletal pain, headache, phosphate decreased, gamma glutamyl transferase increased, lymphocytes decreased, and hypertension. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Kadmon Pharmaceuticals, LLC at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="83a6c027-4d65-476b-9f44-a9b9199f7ddb"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1	Clinical Trial Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely variable conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section>
                           <id root="930cf444-ed3c-4858-b5fa-9749c45a9825"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Chronic Graft versus Host Disease</content>
                              </paragraph>
                              <paragraph>In two clinical trials (Study KD025-213 and Study KD025-208), 83 adult patients with chronic GVHD were treated with REZUROCK 200 mg once daily <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>. The median duration of treatment was 9.2 months (range 0.5 to 44.7 months).</paragraph>
                              <paragraph>Fatal adverse reaction was reported in one patient with severe nausea, vomiting, diarrhea and multi-organ failure.</paragraph>
                              <paragraph>Permanent discontinuation of REZUROCK due to adverse reactions occurred in 18% of patients. The adverse reactions which resulted in permanent discontinuation of REZUROCK in &gt;3% of patients included nausea (4%). Adverse reactions leading to dose interruption occurred in 29% of patients. The adverse reactions leading to dose interruption in ≥2% were infections (11%), diarrhea (4%), and asthenia, dyspnea, hemorrhage, hypotension, liver function test abnormal, nausea, pyrexia, edema, and renal failure with (2% each).</paragraph>
                              <paragraph>The most common (≥20%) adverse reactions, including laboratory abnormalities, were infections, asthenia, nausea, diarrhea, dyspnea, cough, edema, hemorrhage, abdominal pain, musculoskeletal pain, headache, phosphate decreased, gamma glutamyl transferase increased, lymphocytes decreased, and hypertension.</paragraph>
                              <paragraph>Table 2 summarizes the nonlaboratory adverse reactions.</paragraph>
                              <table width="80%" ID="TABLE2">
                                 <caption>Table 2: Nonlaboratory Adverse Reactions in ≥10% Patients with Chronic GVHD Treated with REZUROCK</caption>
                                 <col width="34%" align="left" valign="top"/>
                                 <col width="33%" align="center" valign="top"/>
                                 <col width="33%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th rowspan="2" styleCode="Lrule Rrule" valign="bottom">Adverse Reaction</th>
                                       <th colspan="2" styleCode="Rrule">REZUROCK<br/> 200 mg once daily<br/> (N=83)</th>
                                    </tr>
                                    <tr>
                                       <th align="center" styleCode="Rrule">All Grades  (%)</th>
                                       <th styleCode="Rrule">Grades 3–4 (%)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Infections and infestations</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Infection (pathogen not specified)<footnote ID="K990">infection with an unspecified pathogen includes acute sinusitis, device related infection, ear infection, folliculitis, gastroenteritis, gastrointestinal infection, hordeolum, infectious colitis, lung infection, skin infection, tooth infection, urinary tract infection, wound infection, upper respiratory tract infection, pneumonia, conjunctivitis, sinusitis, respiratory tract infection, bronchitis, sepsis, septic shock.</footnote>
                                       </td>
                                       <td styleCode="Rrule">53</td>
                                       <td styleCode="Rrule">16</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Viral infection<footnote ID="K1003">includes influenza, rhinovirus infection, gastroenteritis viral, viral upper respiratory tract infection, bronchitis viral, Epstein-Barr viremia, Epstein-Barr virus infection, parainfluenzae virus infection, Varicella zoster virus infection, viral infection.</footnote>
                                       </td>
                                       <td styleCode="Rrule">19</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Bacterial infection<footnote ID="K1016">includes cellulitis, Helicobacter infection, Staphylococcal bacteremia, catheter site cellulitis, Clostridium difficile colitis, Escherichia urinary tract infection, gastroenteritis Escherichia coli, Pseudomonas infection, urinary tract infection bacterial.</footnote>
                                       </td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">General disorders and administration site conditions</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Asthenia<footnote ID="K1037">includes fatigue, asthenia, malaise.</footnote>
                                       </td>
                                       <td styleCode="Rrule">46</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Edema<footnote ID="K1050">includes edema peripheral, generalized edema, face edema, localized edema, edema.</footnote>
                                       </td>
                                       <td styleCode="Rrule">27</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pyrexia</td>
                                       <td styleCode="Rrule">18</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Gastrointestinal</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nausea<footnote ID="K1082">includes nausea, vomiting.</footnote>
                                       </td>
                                       <td styleCode="Rrule">42</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">35</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Abdominal pain<footnote ID="K1106">includes abdominal pain, abdominal pain upper, abdominal pain lower.</footnote>
                                       </td>
                                       <td styleCode="Rrule">22</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dysphagia</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Respiratory, thoracic and mediastinal</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dyspnea<footnote ID="K1138">includes dyspnea, dyspnea exertional, apnea, orthopnea, sleep apnea syndrome.</footnote>
                                       </td>
                                       <td styleCode="Rrule">33</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Cough<footnote ID="K1151">includes cough, productive cough.</footnote>
                                       </td>
                                       <td styleCode="Rrule">30</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nasal congestion</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Vascular</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hemorrhage<footnote ID="K1183">includes contusion, hematoma, epistaxis, increased tendency to bruise, conjunctival hemorrhage, hematochezia, mouth hemorrhage, catheter site hemorrhage, hematuria, hemothorax, purpura.</footnote>
                                       </td>
                                       <td styleCode="Rrule">23</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypertension</td>
                                       <td styleCode="Rrule">21</td>
                                       <td styleCode="Rrule">7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Musculoskeletal and connective tissue</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Musculoskeletal pain<footnote ID="K1215">includes pain in extremity, back pain, flank pain, limb discomfort, musculoskeletal chest pain, neck pain, musculoskeletal pain.</footnote>
                                       </td>
                                       <td styleCode="Rrule">22</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Muscle spasm</td>
                                       <td styleCode="Rrule">17</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Arthralgia</td>
                                       <td styleCode="Rrule">15</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Nervous system</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Headache<footnote ID="K1258">includes headache, migraine.</footnote>
                                       </td>
                                       <td styleCode="Rrule">21</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Metabolism and nutrition</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased appetite</td>
                                       <td styleCode="Rrule">17</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Skin and subcutaneous</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Rash<footnote ID="K1298">includes rash, rash maculo-papular, rash erythematous, rash generalized, dermatitis exfoliative.</footnote>
                                       </td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Pruritus<footnote ID="K1310">includes pruritus, pruritus generalized.</footnote>
                                       </td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Table 3 summarizes the laboratory abnormalities in REZUROCK.</paragraph>
                              <table width="90%" ID="TABLE3">
                                 <caption>Table 3: Selected Laboratory Abnormalities in Patients with Chronic GVHD Treated with REZUROCK</caption>
                                 <col width="40%" align="left" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th rowspan="2" styleCode="Lrule Rrule"/>
                                       <th colspan="3" styleCode="Rrule">REZUROCK<br/> 200 mg once daily</th>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <th align="center" styleCode="Rrule">Grade 0–1<br/> Baseline</th>
                                       <th styleCode="Rrule">Grade 2–4<br/> Max Post</th>
                                       <th styleCode="Rrule">Grade 3–4<br/> Max Post</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Parameter</th>
                                       <th styleCode="Rrule">(N)</th>
                                       <th styleCode="Rrule">(%)</th>
                                       <th styleCode="Rrule">(%)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Chemistry</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Phosphate decreased</td>
                                       <td styleCode="Rrule">76</td>
                                       <td styleCode="Rrule">28</td>
                                       <td styleCode="Rrule">7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Gamma Glutamyl Transferase increased</td>
                                       <td styleCode="Rrule">47</td>
                                       <td styleCode="Rrule">21</td>
                                       <td styleCode="Rrule">11</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Calcium decreased</td>
                                       <td styleCode="Rrule">82</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Alkaline Phosphatase increased</td>
                                       <td styleCode="Rrule">80</td>
                                       <td styleCode="Rrule">9</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Potassium increased</td>
                                       <td styleCode="Rrule">82</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Alanine Aminotransferase increased</td>
                                       <td styleCode="Rrule">83</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Creatinine increased</td>
                                       <td styleCode="Rrule">83</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="4" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Hematology</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Lymphocytes decreased</td>
                                       <td styleCode="Rrule">62</td>
                                       <td styleCode="Rrule">29</td>
                                       <td styleCode="Rrule">13</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hemoglobin decreased</td>
                                       <td styleCode="Rrule">79</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Platelets decreased</td>
                                       <td styleCode="Rrule">82</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Neutrophil Count decreased</td>
                                       <td styleCode="Rrule">83</td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="90c3e6a3-f4d6-4e81-9c1c-4a5f017b8620"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Strong CYP3A Inducers</content>: Increase REZUROCK dosage to 200 mg twice daily. (<linkHtml href="#S7.1">7.1</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Proton Pump Inhibitors</content>: Increase REZUROCK dosage to 200 mg twice daily. (<linkHtml href="#S7.1">7.1</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Certain P-gp, OATP1B1, BCRP, and UGT1A1 substrates</content>: Avoid concomitant use with these substrates for which minimal concentration changes may lead to serious toxicities. If coadministration cannot be avoided, decrease the substrates dosage(s) in accordance with the respective Prescribing Information. (<linkHtml href="#S7.2">7.2</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="232dd8ce-7ef9-45cb-9e2d-27f925c341ed"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Effect of Other Drugs on REZUROCK</title>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section>
                           <id root="8aca25d6-6175-4c01-a3b7-07505366d0bb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Strong CYP3A Inducers</content>
                              </paragraph>
                              <paragraph>Coadministration of REZUROCK with strong CYP3A inducers decreases belumosudil exposure <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>, which may reduce the efficacy of REZUROCK. Increase the dosage of REZUROCK when coadministered with strong CYP3A inducers <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b0a8b3db-b124-44b6-8381-0398dd4439a3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Proton Pump Inhibitors</content>
                              </paragraph>
                              <paragraph>Coadministration of REZUROCK with proton pump inhibitors decreases belumosudil exposure <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>, which may reduce the efficacy of REZUROCK. Increase the dosage of REZUROCK when coadministered with proton pump inhibitors <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="0efe8609-e04c-42e7-b99b-03596b9a8b6a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2	Effect of REZUROCK on Other Drugs </title>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section>
                           <id root="ddda4576-6c51-4c24-a80c-88c641d1289b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Certain UGT1A1 substrates</content>
                              </paragraph>
                              <paragraph>Avoid coadministration of REZUROCK with UGT1A1 substrates, for which minimal concentration changes may lead to serious toxicities. If coadministration cannot be avoided, decrease the UGT1A1 substrates dosage(s) in accordance with the respective Prescribing Information.</paragraph>
                              <paragraph>REZUROCK is an inhibitor of UGT1A1. Coadministration of REZUROCK with a UGT1A1 substrate decreased plasma concentrations of the glucuronide metabolite <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>, which may increase the risk of adverse reactions related to sensitive substrates of UGT1A1.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="9edb3b62-e84d-4d90-8827-18d207177193"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Certain P-gp, OATP1B1, and BCRP substrates</content>
                              </paragraph>
                              <paragraph>Avoid coadministration of REZUROCK with P-gp, OATP1B1, and BCRP substrates, for which minimal concentration changes may lead to serious toxicities. If coadministration cannot be avoided, decrease the P-gp, OATP1B1, and BCRP substrates dosage(s) in accordance with the respective Prescribing Information.</paragraph>
                              <paragraph>REZUROCK is an inhibitor of P-gp, OATP1B1, and BCRP. Coadministration of REZUROCK with P-gp, OATP1B1, and BCRP substrates increased their plasma concentrations <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>, which may increase the risk of adverse reactions related to these substrates. </paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="b29c7ca5-57ed-49f1-86f2-2051aeea10d4"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Lactation</content>: Advise not to breastfeed. (<linkHtml href="#S8.2a">8.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Moderate or Severe Hepatic Impairment:</content> Avoid use of REZUROCK in patients with moderate or severe hepatic impairment. (<linkHtml href="#S2.4">2.4</linkHtml>, <linkHtml href="#S8.7">8.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="37b39087-b174-4eba-906e-a228333f3c90"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1	Pregnancy</title>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section>
                           <id root="4de8bcf4-edd5-47ca-840e-5ac37beba881"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on findings from animal studies and the mechanism of action <content styleCode="italics">[see <linkHtml href="#S12.1">Clinical Pharmacology (12.1)</linkHtml>]</content>, REZUROCK can cause fetal harm when administered to pregnant women. There are no available human data on REZUROCK use in pregnant women to evaluate for a drug-associated risk. In animal reproduction studies, administration of belumosudil to pregnant rats and rabbits during the period of organogenesis resulted in adverse developmental outcomes, including alterations to growth, embryo-fetal mortality, and embryo-fetal malformations at maternal exposures (AUC) approximately ≥1.4 (rat) and ≥0.08 (rabbit) times the human exposure (AUC) at the recommended dose <content styleCode="italics">(see <linkHtml href="#DATA">Data</linkHtml>)</content>. Advise pregnant women and females of reproductive potential of the potential risk to the fetus.</paragraph>
                              <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section ID="DATA">
                           <id root="f7d8a7ca-ec34-4b9c-b691-e7320eed8b84"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                           <component>
                              <section ID="ANIMAL_DATA">
                                 <id root="947f80f3-ac70-4ed4-b697-a58b25f5a827"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal data</content>
                                    </paragraph>
                                    <paragraph>Embryo-fetal development studies were conducted in rats with administration of belumosudil to pregnant animals during the period of organogenesis at oral doses of 25, 50, 150, and 300 mg/kg/day in a pilot study and doses of 15, 50, and 150 mg/kg/day in a pivotal study. In the pilot study, maternal toxicity and embryo-fetal developmental effects were observed. Maternal toxicity (reduced body weight gain) occurred at 150 and 300 mg/kg/day doses. Increased post-implantation loss occurred at 50 and 300 mg/kg/day. Fetal-malformations were observed at ≥50 mg/kg/day and included absence of anus and tail, omphalocele, and dome shaped head. The exposure (AUC) at 50 mg/kg/day in rats is approximately 1.4 times the human exposure at the recommended dose of 200 mg.</paragraph>
                                    <paragraph>In an embryo-fetal developmental study in rabbits, pregnant animals administered oral doses of belumosudil at  50, 125, and 225 mg/kg/day during the period of organogenesis resulted in maternal toxicity and embryo-fetal developmental effects. Maternal toxicity (body weight loss and mortality) was observed at doses ≥125 mg/kg/day. Embryo-fetal effects were observed at doses ≥50 mg/kg/day and included spontaneous abortion, increased post-implantation loss, decreased percentage of live fetuses, malformations, and decreased fetal body weight. Malformations included those in the tail (short), ribs (branched, fused or deformed), sternebrae (fused), and neural arches (fused, misaligned, and deformed). The exposure (AUC) at 50 mg/kg/day in rabbits is approximately 0.08 times the human exposure at the recommended dose of 200 mg.</paragraph>
                                 </text>
                                 <effectiveTime value="20250429"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2a">
                     <id root="10297408-2cdf-4506-9e57-184b689c3cf2"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2	Lactation</title>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section>
                           <id root="bb45687d-e680-4ec1-b94a-9c29202ae1a8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data available on the presence of belumosudil or its metabolites in human milk or the effects on the breastfed child, or milk production. Because of the potential for serious adverse reactions from belumosudil in the breastfed child, advise lactating women not to breastfeed during treatment with REZUROCK and for one week after the last dose.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3a">
                     <id root="4357f2e8-41fc-4dab-bfa2-9d2d3b067759"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3	Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>REZUROCK can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section>
                           <id root="ef570127-deec-40c7-8a87-0a223c7edf2c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Testing</content>
                              </paragraph>
                              <paragraph>Verify the pregnancy status of females of reproductive potential prior to initiating treatment with REZUROCK.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="eda983ff-277f-4af6-a702-2a5601d424f8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                           <component>
                              <section>
                                 <id root="b8a64ee8-b8b2-4f89-8427-49ecd89e8595"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Females</paragraph>
                                    <paragraph>Advise females of reproductive potential to use effective contraception during treatment with REZUROCK and for one week after the last dose of REZUROCK. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be informed of the potential hazard to a fetus.</paragraph>
                                 </text>
                                 <effectiveTime value="20250429"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="9907dba1-b377-4fbb-bd67-1f070cabaa39"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Males</paragraph>
                                    <paragraph>Advise males with female partners of reproductive potential to use effective contraception during treatment with REZUROCK and for one week after the last dose of REZUROCK.</paragraph>
                                 </text>
                                 <effectiveTime value="20250429"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3ab20ae1-5b80-4415-b298-51bc69670102"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Infertility</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                           <component>
                              <section>
                                 <id root="8feecaf9-8684-496a-aa0d-0c3622088dc0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Females</paragraph>
                                    <paragraph>Based on findings from rats, REZUROCK may impair female fertility <content styleCode="italics">[see <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250429"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="626e1965-22af-40af-a3ad-8dbe3374df27"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Males</paragraph>
                                    <paragraph>Based on findings from rats and dogs, REZUROCK may impair male fertility <content styleCode="italics">[see <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250429"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="b2671b34-4e2d-4c19-9d2a-460e05345573"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4	Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of REZUROCK have been established in pediatric patients 12 years and older. Use of REZUROCK in this age group is supported by evidence from adequate and well-controlled studies of REZUROCK in adults with additional population pharmacokinetic data demonstrating that age and body weight had no clinically meaningful effect on the pharmacokinetics of drug substance, that the exposure of drug substance is expected to be similar between adults and pediatric patients age 12 years and older, and that the course of disease is sufficiently similar in adult and pediatric patients to allow extrapolation of data in adults to pediatric patients.</paragraph>
                        <paragraph>The safety and effectiveness of REZUROCK in pediatric patients less than 12 years old have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="29a195b9-6ac6-45ed-925e-041f8bbc74b3"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5	Geriatric Use</title>
                     <text>
                        <paragraph>Of the 186 patients with chronic GVHD in clinical studies of REZUROCK, 26% were 65 years and older. No clinically meaningful differences in safety or effectiveness of REZUROCK were observed in comparison to younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="194cc1ed-d074-4e1e-b733-0c70584a3f9e"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Treatment with REZUROCK has not been studied in patients with pre-existing severe renal impairment. For patients with pre-existing severe renal impairment, consider the risks and potential benefits before initiating treatment with REZUROCK <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="0c59b326-9305-4334-8fd9-d5eba4dfc5ab"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>Avoid use in patients with moderate hepatic impairment (Child-Pugh B) or severe hepatic impairment (Child-Pugh C) without liver GVHD <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>No dosage adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A) <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="8a92c326-ed9b-4cd7-9bfe-0bc4e9b8e7de"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Belumosudil is a kinase inhibitor. The active pharmaceutical ingredient is belumosudil mesylate with the molecular formula C<sub>27</sub>H<sub>28</sub>N<sub>6</sub>O<sub>5</sub>S and the molecular weight is 548.62 g/mol. The chemical name for belumosudil mesylate is 2-{3-[4-(1<content styleCode="italics">H</content>-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-<content styleCode="italics">N</content>-(propan-2-yl) acetamide methanesulfonate (1:1). The chemical structure is as follows:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Belumosudil mesylate is a yellow powder that is practically insoluble in water, slightly soluble in methanol and DMF and soluble in DMSO.</paragraph>
                  <paragraph>REZUROCK tablets are for oral administration. Each tablet contains 200 mg of the free base equivalent to 242.5 mg of belumosudil mesylate. The tablet also contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose, magnesium stearate, and microcrystalline cellulose.</paragraph>
                  <paragraph>The tablet film consists of polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide and yellow iron oxide.</paragraph>
               </text>
               <effectiveTime value="20250429"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="102e4ef4-7f84-4e34-8df1-479c24d1575d-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="2815c7c4-8dfc-4b40-897d-2f4b26e173a5"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250429"/>
               <component>
                  <section ID="S12.1">
                     <id root="0f3129c5-dbc7-4a7f-8b94-525bf9c02b1f"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1	Mechanism of Action</title>
                     <text>
                        <paragraph>Belumosudil is an inhibitor of rho-associated, coiled-coil containing protein kinase (ROCK) which inhibits ROCK2 and ROCK1 with IC<sub>50</sub> values of approximately 100 nM and 3 µM, respectively. Belumosudil down-regulated proinflammatory responses via regulation of STAT3/STAT5 phosphorylation and shifting Th17/Treg balance in <content styleCode="italics">ex-vivo</content> or <content styleCode="italics">in vitro</content>-human T cell assays. Belumosudil also inhibited aberrant pro-fibrotic signaling, <content styleCode="italics">in vitro</content>. <content styleCode="italics">In vivo</content>, belumosudil demonstrated activity in animal models of chronic GVHD.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="d848047e-9277-4e58-9429-e092e143b1dc"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2	Pharmacodynamics</title>
                     <text>
                        <paragraph>Belumosudil exposure-response relationships and the time course of pharmacodynamic response are not established.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section>
                           <id root="1b4028cb-077b-44a0-93b1-489ca4a131b9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>At 2.4 times the maximum exposure for approved recommended dose, REZUROCK does not prolong the QT interval to any clinically relevant extent.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="11d7c1fa-9ec7-4a66-b0f7-a2ac8238be2c"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3	Pharmacokinetics</title>
                     <text>
                        <paragraph>The following pharmacokinetic parameters are presented for chronic GVHD patients administered belumosudil 200 mg once daily, unless otherwise specified. The mean (% coefficient of variation, %CV) steady-state AUC and C<sub>max</sub> of belumosudil was 22,700 (48%) h∙ng/mL and 2390 (44%) ng/mL, respectively. Belumosudil C<sub>max</sub> and AUC increased in an approximately proportional manner over a dosage range of 200 and 400 mg (1 to 2 times once daily recommended dosage). The accumulation ratio of belumosudil was 1.4.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section>
                           <id root="49ef312f-0c4d-48ea-ab84-34ed9a161bf5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Median T<sub>max</sub> of belumosudil at steady state was 1.26 to 2.53 hours following administration of 200 mg once daily or twice daily in patients. The mean (%CV) bioavailability was 64% (17%) following a single belumosudil dose in healthy subjects.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                           <component>
                              <section>
                                 <id root="6f5e074b-f7e6-467d-936d-e2c0980e229c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Effect of food</paragraph>
                                    <paragraph>Belumosudil C<sub>max</sub> and AUC increased 2.2 times and 2 times, respectively, following administration of a single belumosudil dose with a high-fat and high-calorie meal (800 to 1,000 calories with approximately 50% of total caloric content of the meal from fat) compared to the fasted state in healthy subjects. Median T<sub>max</sub> was delayed 0.5 hours.</paragraph>
                                 </text>
                                 <effectiveTime value="20250429"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4f22e060-a421-4648-9209-b07e6d1aa1cf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The geometric mean volume of distribution after a single dose of belumosudil in healthy subjects was 184 L (geo CV% 67.7%).</paragraph>
                              <paragraph>Belumosudil binding to human serum albumin and human α<sub>1</sub>-acid glycoprotein was 99.9% and 98.6%, respectively, <content styleCode="italics">in vitro</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="10aa15ed-5527-451e-81ec-8b49fc23d96d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The mean (%CV) elimination half-life of belumosudil was 19 hours (39%), and clearance was 9.83 L/hours (46%) in patients.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                           <component>
                              <section>
                                 <id root="d76b9c3d-d179-40be-9f05-ef4f219a8ee6"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Metabolism</paragraph>
                                    <paragraph>Belumosudil is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8, CYP2D6, and UGT1A9, <content styleCode="italics">in vitro</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250429"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="806099e9-1849-4aee-8bb4-246048fef766"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Excretion</paragraph>
                                    <paragraph>Following a single oral dose of radiolabeled belumosudil in healthy subjects, 85% of radioactivity was recovered in feces (30% as unchanged) and less than 5% in urine.</paragraph>
                                 </text>
                                 <effectiveTime value="20250429"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b1f33164-aeb6-4cf2-bece-681c00ffa654"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>No clinically significant differences in belumosudil pharmacokinetics were observed with regard to age (18 to 77 years), sex, weight (38.6 to 143 kg), or mild to moderate renal impairment (eGFR ≥60 and &lt;90 mL/min/1.72m<sup>2</sup> to eGFR ≥30 and &lt;60 mL/min/1.72m<sup>2</sup>). The effect of severe renal impairment on the pharmacokinetics of belumosudil has not been studied.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                           <component>
                              <section>
                                 <id root="4569556a-5da7-4c50-a2f5-6e440c295c6f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>Following a single 200 mg dose of belumosudil, changes in belumosudil exposure in subjects with varying degrees of hepatic impairment based on Child-Pugh score without liver GVHD relative to subjects with normal hepatic function is shown in Table 4.</paragraph>
                                    <table width="80%">
                                       <caption>Table 4: Effect of Varying Degrees of Hepatic Impairment on Belumosudil Exposure</caption>
                                       <col width="32%" align="left" valign="middle"/>
                                       <col width="17%" align="center" valign="middle"/>
                                       <col width="17%" align="center" valign="middle"/>
                                       <col width="17%" align="center" valign="middle"/>
                                       <col width="17%" align="center" valign="middle"/>
                                       <thead>
                                          <tr styleCode="Botrule">
                                             <th styleCode="Lrule Rrule" rowspan="3" align="center">Hepatic Impairment Category</th>
                                             <th styleCode="Rrule" colspan="4">Changes in Belumosudil Exposure in Subjects with Hepatic Impairment Compared to Subjects with Normal Hepatic Function</th>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <th styleCode="Rrule" colspan="2" align="center">Total (Free + Bound) Concentrations</th>
                                             <th styleCode="Rrule" colspan="2">Free Concentrations</th>
                                          </tr>
                                          <tr>
                                             <th styleCode="Rrule" align="center">C<sub>max</sub>
                                             </th>
                                             <th styleCode="Rrule">AUC</th>
                                             <th styleCode="Rrule">C<sub>max</sub>
                                             </th>
                                             <th styleCode="Rrule">AUC</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Mild (Child-Pugh A)</td>
                                             <td styleCode="Rrule">1.2-fold increase</td>
                                             <td styleCode="Rrule">1.4-fold increase</td>
                                             <td styleCode="Rrule">14% decrease</td>
                                             <td styleCode="Rrule">19% decrease</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" valign="top">Moderate (Child-Pugh B)</td>
                                             <td styleCode="Rrule">6% decrease</td>
                                             <td styleCode="Rrule">1.5-fold increase</td>
                                             <td styleCode="Rrule">12% decrease</td>
                                             <td styleCode="Rrule">1.4-fold increase</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule" valign="top">Severe (Child-Pugh C)</td>
                                             <td styleCode="Rrule">1.3-fold increase</td>
                                             <td styleCode="Rrule">4.2-fold increase</td>
                                             <td styleCode="Rrule">5.4-fold increase</td>
                                             <td styleCode="Rrule">16-fold increase</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20250429"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3f2d85ba-46d8-4cbf-b8de-6dd38c556ae3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                           <component>
                              <section>
                                 <id root="a1d92a72-2b6d-4784-ae1b-777ae1d44f65"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Clinical studies and model-informed approaches</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250429"/>
                                 <component>
                                    <section>
                                       <id root="1aa45a77-b054-4b8c-9b87-1c3e09b0abf2"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>Effects of other drugs on Belumosudil</paragraph>
                                       </text>
                                       <effectiveTime value="20250429"/>
                                       <component>
                                          <section>
                                             <id root="065ea37b-ddbe-4ee6-818a-465f25943df5"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>Strong Cytochrome P450 (CYP) 3A Inhibitors: There was no clinically meaningful effect on belumosudil exposure when coadministered with itraconazole in healthy subjects.</paragraph>
                                             </text>
                                             <effectiveTime value="20250429"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section>
                                             <id root="8aa45e90-6acd-45ad-add4-43d31ee68c51"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>Strong CYP3A Inducers: Coadministration of rifampin decreased belumosudil C<sub>max</sub> by 59% and AUC by 72% in healthy subjects.</paragraph>
                                             </text>
                                             <effectiveTime value="20250429"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section>
                                             <id root="83051f5b-2476-4698-8c46-bc274339cbe6"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>Moderate CYP3A Inducers: Coadministration of efavirenz is predicted to decrease belumosudil C<sub>max</sub> by 19% and AUC by 35% in healthy subjects.</paragraph>
                                             </text>
                                             <effectiveTime value="20250429"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section>
                                             <id root="6aac3dd9-456b-4172-9986-c32cc36dfa25"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>Proton Pump Inhibitors: Coadministration of rabeprazole decreased belumosudil C<sub>max</sub> by 87% and AUC by 80%, and omeprazole decreased belumosudil C<sub>max</sub> by 68% and AUC by 47% in healthy subjects.</paragraph>
                                             </text>
                                             <effectiveTime value="20250429"/>
                                          </section>
                                       </component>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="f9389422-a3ad-4e1a-9384-9d5ba6d1b29e"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>Effects of Belumosudil on other drugs</paragraph>
                                       </text>
                                       <effectiveTime value="20250429"/>
                                       <component>
                                          <section>
                                             <id root="f9e53f46-8001-4562-bdfa-eccf07f470ff"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>CYP3A Substrates: Coadministration of belumosudil is predicted to increase midazolam (a sensitive CYP3A substrate) C<sub>max</sub> and AUC approximately 1.3- and 1.5-fold, respectively.</paragraph>
                                             </text>
                                             <effectiveTime value="20250429"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section>
                                             <id root="f3dffed8-5e61-450d-9aad-3ed0f5f12857"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>CYP2C9 Substrates: Coadministration of belumosudil is not expected to have clinically meaningful effect on the exposure of CYP2C9 substrates (such as warfarin).</paragraph>
                                             </text>
                                             <effectiveTime value="20250429"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section>
                                             <id root="92e5e62f-a7fa-4890-8da7-408191a194d1"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>CYP2C8 Substrates: Coadministration of belumosudil is not expected to have clinically meaningful effect on the exposure of CYP2C8 substrates that are not an OATP1B1 substrate.</paragraph>
                                             </text>
                                             <effectiveTime value="20250429"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section>
                                             <id root="2ef19c10-b0ce-4796-a83a-8eec043c95fc"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">UGT1A1 Substrates:</content> Coadministration of belumosudil decreased raltegravir glucuronide (metabolite formed via the UGT1A1 pathway) C<sub>max</sub> by 42% and AUC by 40%.</paragraph>
                                             </text>
                                             <effectiveTime value="20250429"/>
                                          </section>
                                       </component>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3c5a5723-80d8-4597-9ef3-eebfa2c61c94"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Transporter systems</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250429"/>
                                 <component>
                                    <section>
                                       <id root="e5a98876-cffb-4ed5-b881-940df9e52451"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">OATP1B1/BCRP Substrates</content>: Coadministration of belumosudil increased rosuvastatin (OATP1B1 and BCRP substrate) C<sub>max</sub> and AUC by 3.6- and 4.6-fold, respectively<content styleCode="italics">.</content>
                                          </paragraph>
                                       </text>
                                       <effectiveTime value="20250429"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="e1a8170c-56e1-46d9-8301-bfc3dcad60da"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">P-glycoprotein (P-gp) Substrates:</content>  Coadministration of belumosudil increased dabigatran (P-gp substrate) C<sub>max</sub> and AUC by 2-fold.</paragraph>
                                       </text>
                                       <effectiveTime value="20250429"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="48abcfb1-2069-4107-a944-d651d406d9f5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Vitro</content> studies</paragraph>
                                 </text>
                                 <effectiveTime value="20250429"/>
                                 <component>
                                    <section>
                                       <id root="6a2da1e1-2e0d-4ecd-b588-67ca9d4b22e9"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Transporter Systems</content>: Belumosudil is a substrate of P-gp. Belumosudil inhibits BCRP, P-gp, and OATP1B1 at clinically relevant concentrations.</paragraph>
                                       </text>
                                       <effectiveTime value="20250429"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="2b191f4b-b498-4513-b9a0-f79a1ea4432f"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Enzymes Systems</content>: Belumosudil is an inhibitor of CYP1A2, CYP2C19, CYP2D6, UGT1A1 and UGT1A9.</paragraph>
                                       </text>
                                       <effectiveTime value="20250429"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="be6193fd-360a-4881-be69-c5edb571307f"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13	NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250429"/>
               <component>
                  <section ID="S13.1">
                     <id root="e3e49fb7-8a9b-4fc9-b043-e1a8da11b23c"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section>
                           <id root="a2508ac8-027e-4f5c-a4c5-1b7f1db4e126"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Belumosudil did not result in any carcinogenic effect in a 6-month CByB6F1-Tg (HRAS)2Jic hemizygous mouse study at oral doses up to 15 mg/kg/day in female and 30 mg/kg/day in male mice.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="105cdf09-72d9-4987-96f1-6b3d5612b3a1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Belumosudil was not genotoxic in an <content styleCode="italics">in vitro</content> bacterial mutagenicity (Ames) assay, <content styleCode="italics">in vitro</content> chromosome aberration assay in human peripheral blood lymphocytes (HPBL) or an <content styleCode="italics">in vivo</content> rat bone marrow micronucleus assay.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="957d68ea-238e-46d1-9714-bbebbae8cae6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>In a combined male and female rat fertility and early embryonic development study, belumosudil-treated male animals were mated with untreated females, or untreated males were mated with belumosudil-treated females. Belumosudil was administered orally at doses of 50, 150 or 275 mg/kg/day to male rats 70 days prior to and throughout the mating period, and to female rats 14 days prior to mating and up to Gestation Day 7. At the dose of 275 mg/kg/day, adverse findings in female rats (treated with belumosudil or untreated but mated with treated males) regarding early embryonic development included increased pre- or post-implantation loss and decreased number of viable embryos. Administration of belumosudil to male rats at a dose of 275 mg/kg/day resulted in abnormal sperm findings (reduced motility, reduced count, and increased percentage of abnormal sperm), and testes/epididymis organ changes (reduced weight and degeneration). Fertility was reduced in both treated males or females at the 275 mg/kg/day dose and reached statistical significance in males. Adverse changes in male and female reproductive organs also occurred in general 3-month and 6-month toxicology studies. In males, findings included spermatozoa degeneration at a belumosudil dose of 50 mg/kg/day in rats and 35 mg/kg/day in dogs. The exposure (AUC) at the doses of 50 mg/kg/day in male rats and 35 mg/kg/day in male dogs is approximately equivalent to the clinical exposure at the recommended dose of 200 mg/day. Changes were reversible in dogs but not fully reversible in rats. In female rats, changes included decreased follicular development in ovaries and lower uterine weights that correlated with uterine/cervical hypoplasia at 275 mg/kg/day [corresponding to 9 times exposure in patients at the recommended dose of 200 mg/day]. Changes were fully reversed during the 4-week recovery period.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="7f856833-53cc-4a17-a98c-5b935e296a6e"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14	CLINICAL STUDIES</title>
               <effectiveTime value="20250429"/>
               <component>
                  <section ID="S14.1">
                     <id root="75bac83c-cd41-475f-9099-145e034b85b1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1	Chronic Graft versus Host Disease</title>
                     <text>
                        <paragraph>Study KD025-213 (NCT03640481) was a randomized, open-label, multicenter study of REZUROCK for treatment of patients with chronic GVHD who had received 2 to 5 prior lines of systemic therapy and required additional treatment. Patients were excluded from the studies if platelets were &lt;50 × 10<sup>9</sup>/L; absolute neutrophil count &lt;1.5 × 10<sup>9</sup>/L; AST or ALT &gt;3 × ULN; total bilirubin &gt;1.5 × ULN; QTc(F) &gt;480 ms; eGFR &lt;30 mL/min/1.73 m<sup>2</sup>; or FEV1 ≤39%. There were 66 patients treated with REZUROCK 200 mg taken orally once daily. Concomitant treatment with supportive care therapies for chronic GVHD was permitted. Concomitant treatment with GVHD prophylaxis and standard care systemic chronic GVHD therapies was permitted as long as the subject has been on a stable dose for at least 2 weeks prior to study. Initiation of new systemic chronic GVHD therapy while on study was not permitted.</paragraph>
                        <paragraph>Demographics and baseline characteristics are summarized in Table 5.</paragraph>
                        <table width="80%" ID="TABLE5">
                           <caption>Table 5: Demographics and Baseline Characteristics of Patients with Chronic GVHD</caption>
                           <col width="70%" align="left" valign="top"/>
                           <col width="30%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">REZUROCK<br/> 200 mg once daily<br/> (N=65)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Age, Median, Years (minimum, maximum)</td>
                                 <td styleCode="Rrule">53 (21, 77)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Age ≥65 Years, n (%)</td>
                                 <td styleCode="Rrule">17 (26)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Male, n (%)</td>
                                 <td styleCode="Rrule">42 (65)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Race, n (%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  White</td>
                                 <td styleCode="Rrule">54 (83)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Black</td>
                                 <td styleCode="Rrule">6 (9)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Other or Not Reported</td>
                                 <td styleCode="Rrule">5 (8)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Median (range) time (months) from Chronic GVHD Diagnosis</td>
                                 <td styleCode="Rrule">25.3 (1.9, 162.4)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">≥4 Organs Involved, n (%)</td>
                                 <td styleCode="Rrule"> 31 (48)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Median (range) Number of Prior Lines of Therapy</td>
                                 <td styleCode="Rrule">3 (2, 6)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="2" styleCode="Lrule Rrule">Number of Prior Lines of Therapy, n (%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  2</td>
                                 <td styleCode="Rrule">23 (35)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  3</td>
                                 <td styleCode="Rrule">12 (19)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  4</td>
                                 <td styleCode="Rrule">15 (23)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  ≥5</td>
                                 <td styleCode="Rrule">15 (23)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Prior chronic GVHD treatment with ibrutinib, n (%)</td>
                                 <td styleCode="Rrule">21 (32)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Prior chronic GVHD treatment with ruxolitinib, n (%)</td>
                                 <td styleCode="Rrule">20 (31)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Refractory to Last Therapy, n (%<footnote ID="K2751">Denominator excludes patients with unknown status</footnote>)</td>
                                 <td styleCode="Rrule">43/55 (78)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Severe chronic GVHD, n (%)</td>
                                 <td styleCode="Rrule">46 (71)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Median (range) Global Severity Rating</td>
                                 <td styleCode="Rrule">7 (2, 9)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Median (range) Lee Symptom Scale Score at baseline</td>
                                 <td styleCode="Rrule">27 (7, 56)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Median (range) Corticosteroid dose at baseline (PE/kg)<footnote ID="K2785">Prednisone equivalents/kilogram</footnote>
                                 </td>
                                 <td styleCode="Rrule">0.19 (0.03, 0.95)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The efficacy of REZUROCK was based on overall response rate (ORR) through Cycle 7 Day 1 where overall response included complete response or partial response according to the 2014 NIH Response Criteria. The ORR results are presented in Table 6. The ORR was 75% (95% CI: 63, 85). The median duration of response, calculated from first response to progression, death, or new systemic therapies for chronic GVHD, was 1.9 months (95% CI: 1.2, 2.9). The median time to first response was 1.8 months (95% CI: 1.0, 1.9). In patients who achieved response, no death or new systemic therapy initiation occurred in 62% (95% CI: 46, 74) of patients for at least 12 months since response.</paragraph>
                        <table width="50%" ID="TABLE6">
                           <caption>Table 6: Overall Response Rate through Cycle 7 Day 1 for Patients with Chronic GVHD in Study KD025-213</caption>
                           <col width="65%" align="left" valign="top"/>
                           <col width="35%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">REZUROCK<br/> 200 mg once daily<br/> (N=65)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Overall Response Rate (ORR)</content>
                                 </td>
                                 <td styleCode="Rrule">49 (75%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">95% Confidence Interval<footnote ID="K2836">Estimated using Clopper-Pearson method</footnote>
                                 </td>
                                 <td styleCode="Rrule">(63%, 85%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Complete Response</td>
                                 <td styleCode="Rrule">4 (6%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">  Partial Response</td>
                                 <td styleCode="Rrule">45 (69%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>ORR results were supported by exploratory analyses of patient-reported symptom bother which showed at least a 7-point decrease in the Lee Symptom Scale summary score through Cycle 7 Day 1 in 52% (95% CI: 40, 65) of patients.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="35dfaf4c-437f-4d2d-a89b-42ea68a9fe10"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16	HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>REZUROCK 200 mg tablets are supplied as pale yellow film-coated oblong tablets containing 200 mg of belumosudil (equivalent to 242.5 mg belumosudil mesylate). Each tablet is debossed with "KDM" on one side and "200" on the other side and is packaged as follows:</paragraph>
                  <list listType="unordered">
                     <item>200 mg tablets in 30 count bottle: NDC 79802-200-30</item>
                  </list>
               </text>
               <effectiveTime value="20250429"/>
               <component>
                  <section>
                     <id root="0594ac6f-0a6d-4ed1-8ecb-15345abf1435"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store at room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</paragraph>
                        <paragraph>Dispense to patient in original container only. Store in original container to protect from moisture. Replace cap securely each time after opening. Do not discard desiccant.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="88596efd-410e-4a37-8abd-175dfa3739d5"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17	PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
               </text>
               <effectiveTime value="20250429"/>
               <component>
                  <section>
                     <id root="24c57b9f-8448-43bc-bebf-32316095c765"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Embryo-fetal Toxicity:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>
                              </content>, <content styleCode="italics">
                                 <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3a">8.3)</linkHtml>].</content>
                           </item>
                           <item>Advise females of reproductive potential to use effective contraceptive during treatment with REZUROCK and for one week after the last dose <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                           </item>
                           <item>Advise males with female partners of reproductive potential to use effective contraceptive during treatment with REZUROCK and for one week after the last dose <content styleCode="italics">[see <linkHtml href="#S8.3a">Use in Specific Populations (8.3)</linkHtml>]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="e8bd23bf-95ab-4b0c-a921-e6a9e6f7d7ac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Advise women not to breastfeed during treatment with REZUROCK and for one week after the last dose <content styleCode="italics">[see <linkHtml href="#S8.2a">Use in Specific Populations (8.2)</linkHtml>]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b9f0e049-0d59-4f2d-ba97-3428e2ac9652"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Advise males and females of reproductive potential that REZUROCK may impair fertility <content styleCode="italics">[see <linkHtml href="#S8.3a">Use in Specific Populations (8.3)</linkHtml>].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7df63509-4763-4ad5-9e00-4feafe6252f4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Administration</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Inform patients to take REZUROCK orally once daily with food according to their physician's instructions and that the oral dosage (tablets) should be swallowed whole with a glass of water, without cutting, crushing or chewing the tablets approximately the same time each day <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>].</content>
                           </item>
                           <item>Advise patients that in the event of a missed daily dose of REZUROCK, it should be taken as soon as possible on the same day with a return to the normal schedule the following day. Patients should not take extra doses to make up the missed dose <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="26ef02c2-6778-4e1b-964a-1c2a8121181c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Advise patients to inform their health care providers of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="2fca18b2-8248-4e6a-aeeb-71db1ed6df6a"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Distributed and marketed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Kadmon Pharmaceuticals, LLC</content>
                     <br/>Morristown, NJ 07960<br/>                     A SANOFI COMPANY<br/>1-800-633-1610</paragraph>
                  <paragraph>REZUROCK<sup>®</sup> is a registered trademark of Kadmon Pharmaceuticals, LLC. <br/>© 2025 Kadmon Pharmaceuticals, LLC. All rights reserved.</paragraph>
                  <paragraph>For patent information: https://www.sanofi.us/en/products-and-resources/patents</paragraph>
               </text>
               <effectiveTime value="20250429"/>
            </section>
         </component>
         <component>
            <section>
               <id root="ea6daf6a-0d21-4d1c-9b4b-18543e04e259"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="40%" align="left" valign="top"/>
                     <col width="30%" align="left" valign="top"/>
                     <col width="30%" align="right" valign="top"/>
                     <tfoot>
                        <tr>
                           <td colspan="2" align="left">This Patient Information has been approved by the U.S. Food and Drug Administration</td>
                           <td align="right">Revised: 4/2025</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td colspan="3" align="center" styleCode="Lrule Rrule">
                              <content styleCode="bold">PATIENT INFORMATION</content>
                              <br/>REZUROCK (REZ-ur-ok)<br/>(belumosudil)<br/>tablets</td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is REZUROCK?</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">REZUROCK is a prescription medicine used to treat adults and children 12 years of age and older with chronic graft-versus-host disease (chronic GVHD) after you have received at least 2 prior treatments (systemic therapy) and they did not work.<br/> It is not known if REZUROCK is safe and effective in children less than 12 years old.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">Before taking REZUROCK, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have kidney or liver problems.</item>
                                 <item>are pregnant or plan to become pregnant. REZUROCK can harm your unborn baby. If you are able to become pregnant, your healthcare provider will do a pregnancy test before starting treatment with REZUROCK. Tell your healthcare provider if you become pregnant or think you may be pregnant during treatment with REZUROCK.<list listType="unordered" styleCode="Circle">
                                       <item>
                                          <content styleCode="bold">Females</content> who can become pregnant should use effective birth control during treatment with REZUROCK and for 1 week after the last dose.</item>
                                       <item>
                                          <content styleCode="bold">Males</content> with female partners who can become pregnant should use effective birth control during treatment with REZUROCK and for 1 week after the last dose.</item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if REZUROCK passes into breast milk. Do not breastfeed during treatment with REZUROCK and for 1 week after the last dose.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. REZUROCK may affect the way other medicines work, and other medicines may affect the way REZUROCK works.<br/> Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I take REZUROCK?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take REZUROCK exactly as your healthcare provider tells you to take it.</item>
                                 <item>Do not change your dose or stop taking REZUROCK without first talking to your healthcare provider.</item>
                                 <item>Take REZUROCK 1 time a day with a meal.</item>
                                 <item>Take REZUROCK at about the same time each day.</item>
                                 <item>Swallow REZUROCK tablets whole with a glass of water.</item>
                                 <item>Do not cut, crush, or chew REZUROCK tablets.</item>
                                 <item>Your healthcare provider will do blood tests to check your liver at least 1 time a month during treatment with REZUROCK.</item>
                                 <item>If you miss a dose of REZUROCK, take it as soon as you remember on the same day. Take your next dose of REZUROCK at your regular time on the next day. Do not take extra doses of REZUROCK to make up for a missed dose.</item>
                                 <item>If you take too much REZUROCK, call your healthcare provider or go to the nearest hospital emergency room right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of REZUROCK?<br/> The most common side effects of REZUROCK include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>infections</item>
                                 <item>tiredness or weakness</item>
                                 <item>nausea</item>
                                 <item>diarrhea</item>
                                 <item>shortness of breath</item>
                                 <item>cough</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>swelling</item>
                                 <item>bleeding</item>
                                 <item>stomach (abdominal) pain</item>
                                 <item>muscle or bone pain</item>
                                 <item>headache</item>
                                 <item>high blood pressure</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">Your healthcare provider may change your dose of REZUROCK, temporarily stop, or permanently stop treatment with REZUROCK if you have certain side effects.</content>
                              <br/> REZUROCK may affect fertility in males and females. Talk to your healthcare provider if this is a concern for you.<br/> These are not all the possible side effects of REZUROCK.<br/> Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Kadmon Pharmaceuticals, LLC at 1-800-633-1610.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store REZUROCK?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store REZUROCK at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                                 <item>Keep REZUROCK in its original container. The REZUROCK bottle contains a desiccant packet to help keep your tablets dry (protect from moisture). Keep the desiccant in the bottle.</item>
                                 <item>Tightly close the REZUROCK bottle after you take your dose.</item>
                              </list>
                              <content styleCode="bold">Keep REZUROCK and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of REZUROCK.</content>
                              <br/> Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use REZUROCK for a condition for which it was not prescribed. Do not give REZUROCK to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about REZUROCK that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in REZUROCK?<br/> Active ingredient:</content> belumosudil mesylate<br/>
                              <content styleCode="bold">Inactive ingredients:</content>
                              <br/> Tablet core: colloidal silicon dioxide, croscarmellose sodium, hypromellose, magnesium stearate, and microcrystalline cellulose.<br/> Tablet coating: polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide and yellow iron oxide.<br/> Distributed and marketed by <content styleCode="bold">Kadmon Pharmaceuticals, LLC,</content> Morristown, NJ 07960, A SANOFI COMPANY<br/> REZUROCK<sup>®</sup> is a registered trademark of Kadmon Pharmaceuticals, LLC<br/> © 2025 Kadmon Pharmaceuticals, LLC.<br/> All rights reserved.<br/> For more information, call 1-800-633-1610 or go to www.REZUROCK.com.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250429"/>
            </section>
         </component>
         <component>
            <section>
               <id root="55eac60c-f94c-4f6e-b766-08ef979c0443"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 200 mg Tablet Bottle Carton</title>
               <text>
                  <paragraph>NDC 79802-200-30<br/> Rx only</paragraph>
                  <paragraph>REZUROCK<sup>®</sup>
                     <br/> (belumosudil) tablets</paragraph>
                  <paragraph>200 mg</paragraph>
                  <paragraph>Swallow tablets whole. Do not cut,<br/> crush, or chew the tablets.</paragraph>
                  <paragraph>30 Tablets</paragraph>
                  <paragraph>sanofi</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20250429"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 200 mg Tablet Bottle Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="102e4ef4-7f84-4e34-8df1-479c24d1575d-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>